Headquartered in Hercules, CA·Fiscal year ends December·NYSE: BIO·bio-rad.com
About Bio-Rad
Bio-Rad Laboratories develops, manufactures and markets a broad range of products for the life science research and clinical diagnostics markets, through two reporting segments.
- **Clinical Diagnostics (about 61% of Q3 2026 sales):** quality systems (quality control products) and diabetes testing products for hospitals and clinical laboratories.
- **Life Science (about 39%):** research tools including Droplet Digital PCR systems, ChemiDoc imaging systems, and process chromatography resins and pre-packed columns (Nuvia, Foresight Pro) used in biopharmaceutical manufacturing.
Customers include universities, research institutions, hospitals, biopharmaceutical companies, and clinical, food safety and environmental quality laboratories. Sales are spread across the Americas, EMEA and Asia Pacific. The company employed approximately 7,100 people and generated $2.6 billion in revenue in 2025.
Bio-Rad holds a significant equity investment in Sartorius AG, whose fair value changes materially swing reported GAAP earnings. It is currently executing a transformation program that includes restructuring and reprioritization of R&D programs. Updated
Pre-Market Stock Futures: Futures are trading lower on Tuesday morning after investors returned from the three-day Easter weekend to find a stock market ready to rally after some promising news on the…
These four Jefferies stock picks in the health care space offer outstanding upside potential for investors long term and look like very solid ideas for the rest of 2021, especially with an…
Bio-Rad Laboratories develops, manufactures and markets a broad range of products for the life science research and clinical diagnostics markets, through two reporting segments. - **Clinical Diagnostics (about 61% of Q3 2026 sales):** quality systems (quality control products) and diabetes testing products for…
What is the BIO stock price target?
24/7 Wall St.'s 12-month price target for BIO is $441.32, rated Buy. The Wall Street consensus target is $356.67. BIO price prediction →